These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective. Swedberg MD Behav Pharmacol; 2013 Sep; 24(5-6):396-402. PubMed ID: 23907375 [TBL] [Abstract][Full Text] [Related]
8. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Carter LP; Griffiths RR Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S14-25. PubMed ID: 19443137 [TBL] [Abstract][Full Text] [Related]
10. Preference procedures for testing the abuse liability of drugs in humans. De Wit H Br J Addict; 1991 Dec; 86(12):1579-86. PubMed ID: 1786490 [TBL] [Abstract][Full Text] [Related]
11. How good are current approaches to nonclinical evaluation of abuse and dependence? Moser P; Wolinsky T; Duxon M; Porsolt RD J Pharmacol Exp Ther; 2011 Mar; 336(3):588-95. PubMed ID: 21098089 [TBL] [Abstract][Full Text] [Related]
12. Abuse liability studies of opioid agonist-antagonists in humans. Preston KL; Jasinski DR Drug Alcohol Depend; 1991 Jun; 28(1):49-82. PubMed ID: 1884671 [TBL] [Abstract][Full Text] [Related]
14. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Foltin RW; Fischman MW Drug Alcohol Depend; 1991 Jun; 28(1):3-48. PubMed ID: 1679387 [TBL] [Abstract][Full Text] [Related]
15. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. de Wit H; Griffiths RR Drug Alcohol Depend; 1991 Jun; 28(1):83-111. PubMed ID: 1679388 [TBL] [Abstract][Full Text] [Related]
16. Assessing abuse liability during drug development: changing standards and expectations. Schoedel KA; Sellers EM Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799 [TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of compounds for their physical dependence potential and abuse liability. XIII. Drug Testing Program of the Committee on Problems of Drug Dependence, Inc. Jacobson AE NIDA Res Monogr; 1989; 95():556-77. PubMed ID: 2641053 [No Abstract] [Full Text] [Related]
19. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse. Swedberg MD J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786 [TBL] [Abstract][Full Text] [Related]
20. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Born S; Gauvin DV; Mukherjee S; Briscoe R Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]